Vincerx Pharma Files 2025 Proxy Statement

TL;DR

Vincerx Pharma (VINC) filed its proxy statement for 2025. Get ready to vote.

AI Summary

Vincerx Pharma, Inc. filed a Definitive Proxy Statement (DEF 14A) on December 10, 2024, for its fiscal year ending December 31, 2025. The company, formerly known as LifeSci Acquisition Corp. until December 6, 2019, and Vincera Pharma, Inc. until December 23, 2020, is involved in the pharmaceutical preparations industry. The filing is a standard proxy statement, indicating it's for shareholder voting purposes.

Why It Matters

This filing is crucial for shareholders as it outlines important information regarding upcoming votes, executive compensation, and corporate governance matters for Vincerx Pharma, Inc.

Risk Assessment

Risk Level: low — This is a routine DEF 14A filing, which is standard for publicly traded companies and does not inherently indicate new risks.

Key Numbers

• 2025 — Fiscal Year End (The proxy statement covers the reporting period for the fiscal year ending in 2025.)
• 1231 — Fiscal Year End (The company's fiscal year ends on December 31st.)

Key Players & Entities

• Vincerx Pharma, Inc. (company) — Registrant
• LifeSci Acquisition Corp. (company) — Former Company Name
• Vincera Pharma, Inc. (company) — Former Company Name
• 20250116 (date) — Conformed Period of Report
• 20241210 (date) — Filing Date

FAQ

Key Financial Figures

• $1.00 — maintain a minimum closing bid price of $1.00 per share, and Nasdaq Listing Rule 5810

Filing Documents

• d852912ddef14a.htm (DEF 14A) — 223KB
• g852912dsp026.jpg (GRAPHIC) — 124KB
• g852912dsp027.jpg (GRAPHIC) — 122KB
• g852912g53p02.jpg (GRAPHIC) — 35KB
• 0001193125-24-274329.txt ( ) — 601KB

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 21 STOCKHOLDER PROPOSALS FOR THE 2025 ANNUAL MEETING 23 OTHER MATTERS 23 WHERE YOU CAN FIND ADDITIONAL INFORMATION 23 i Table of Contents 260 Sheridan Avenue, Suite 400 Palo Alto, CA 94306 PROXY STATEMENT Information Concerning Voting and Solicitation This Proxy Statement (this Proxy Statement) is being furnished to you in connection with the solicitation by the board of directors of Vincerx Pharma, Inc., a Delaware corporation (we, us, our, Vincerx or the Company), of proxies in the accompanying form to be used at the Special Meeting of Stockholders of the Company to be held virtually on Thursday, January 16, 2025 at 10:00 a.m., Pacific Time, and any adjournments or postponements thereof (the Special Meeting). This Proxy Statement is being mailed to stockholders on or about December 12, 2024. Questions and Answers About the Proxy Materials and the Special Meeting Why am I receiving these materials? Our board of directors is soliciting your proxy to vote at the Special Meeting, including at any adjournments or postponements of the meeting. The Special Meeting will be held virtually. You are invited to attend the Special Meeting via live audio webcast to vote electronically on the proposals described in this Proxy Statement. However, you do not need to attend the meeting to vote your shares. Instead, you may follow the instructions below to submit your proxy by Internet or mail. We are sending this Proxy Statement to our stockholders of record and beneficial owners as of the close of business on November 20, 2024, which is the record date for the Special Meeting (the Record Date). Stockholders are encouraged to vote and submit proxies in advance of the Special Meeting by Internet or mail as early as possible to ensure their votes are counted. What proposal will be voted on at the Special Meeting? One proposal will be voted on at the Special Meeting: Proposal 1: Th

View Full Filing

View this DEF 14A filing on SEC EDGAR